These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32744395)

  • 1. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study.
    Miura H; Sakaguchi K; Otowa-Suematsu N; Yamada T; So A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
    Diabetes Obes Metab; 2020 Dec; 22(12):2356-2363. PubMed ID: 32744395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2).
    Miura H; Sakaguchi K; Okada Y; Otowa-Suematsu N; Yamada T; So A; Komada H; Hirota Y; Kishi M; Takeda A; Tominaga Y; Nakamura T; Kuroki Y; Matsuda T; Iida K; Kajikawa M; Ohara T; Yokota K; Hara K; Tateya S; Tamori Y; Ogawa W
    Diabetes Ther; 2018 Dec; 9(6):2399-2406. PubMed ID: 30341665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
    Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
    Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial.
    Cindro PV; Krnić M; Modun D; Smajić B; Vuković J
    BMC Endocr Disord; 2021 Apr; 21(1):86. PubMed ID: 33926446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin glargine using continuous glucose monitoring: A randomized, cross-over, pilot study.
    Onda Y; Nishimura R; Ando K; Takahashi H; Tsujino D; Utsunomiya K
    Diabetes Res Clin Pract; 2016 Oct; 120():149-55. PubMed ID: 27562434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang Y; Long C; Li T; Chen Q
    Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.
    Takahashi H; Nishimura R; Onda Y; Ando K; Tsujino D; Utsunomiya K
    Expert Opin Pharmacother; 2017 Mar; 18(4):335-342. PubMed ID: 28234565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Impact of Insulin Degludec U100 and Insulin Glargine U300 on Glycemic Variability and Oxidative Stress in Insulin-Naive Patients With Type 2 Diabetes Mellitus: Pilot Study for a Randomized Trial.
    Vrebalov Cindro P; Krnić M; Modun D; Vuković J; Tičinović Kurir T; Kardum G; Rušić D; Šešelja Perišin A; Bukić J
    JMIR Form Res; 2022 Jul; 6(7):e35655. PubMed ID: 35802405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
    Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
    Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study).
    Moser O; Müller A; Aberer F; Aziz F; Kojzar H; Sourij C; Obermayer A; Abbas F; Birnbaumer P; Lenz J; Mursic I; Sternad C; Hönger L; Ziko H; Pferschy PN; Tripolt N; Sourij H
    Diabetes Technol Ther; 2023 Mar; 25(3):161-168. PubMed ID: 36516429
    [No Abstract]   [Full Text] [Related]  

  • 15. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
    Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
    Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.
    Koehler G; Heller S; Korsatko S; Roepstorff C; Rasmussen S; Haahr H; Pieber TR
    Diabetologia; 2014 Jan; 57(1):40-9. PubMed ID: 24057153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
    Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
    Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.